MCID: SFT003
MIFTS: 58

Soft Tissue Sarcoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Soft Tissue Sarcoma

MalaCards integrated aliases for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 53 29 43
Sarcoma, Soft Tissue 40
Sarcoma 73

Classifications:



External Ids:

UMLS 73 C1261473

Summaries for Soft Tissue Sarcoma

NIH Rare Diseases : 53 Soft tissuesarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. These tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. Many people with early soft tissue sarcoma have no signs or symptoms of the condition. When present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. Most cases occur sporadically in people with little to no family history of the condition. People who have previously received radiation therapy and those with certain inherited disorders (such as Gorlin syndrome, Gardner syndrome, Li-Fraumeni syndrome, Tuberous sclerosis, neurofibromatosis type 1, and Werner syndrome) have an increased risk of developing a soft tissue sarcoma. The best treatment options depend on many factors but may include surgery, chemotherapy, and radiation therapy.

MalaCards based summary : Soft Tissue Sarcoma, also known as sarcoma, soft tissue, is related to myxoid liposarcoma and rhabdomyosarcoma 2. An important gene associated with Soft Tissue Sarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. The drugs Doxorubicin and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are endocrine/exocrine gland and cardiovascular system

MedlinePlus : 43 Your soft tissues connect, support, or surround other tissues. Examples include your muscles, tendons, fat, and blood vessels. Soft tissue sarcoma is a cancer of these soft tissues. There are many kinds, based on the type of tissue they started in. They may cause a lump or swelling in the soft tissue. Sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. No one knows exactly what causes these cancers. They are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. Doctors diagnose soft tissue sarcomas with a biopsy. Treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. NIH: National Cancer Institute

Wikipedia : 76 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 223)
# Related Disease Score Top Affiliating Genes
1 myxoid liposarcoma 32.7 EWSR1 MDM2 TP53
2 rhabdomyosarcoma 2 32.6 EWSR1 FOXO1 MDM2
3 kaposi sarcoma 31.8 TNF TP53 VEGFA
4 muscle cancer 31.7 EWSR1 FOXO1 MDM2 TP53
5 li-fraumeni syndrome 31.2 BCL2 EGFR MDM2 TP53
6 gastrointestinal stromal tumor 31.1 EGFR MKI67 TP53 VEGFA
7 histiocytoma 30.9 EWSR1 MDM2 TP53
8 rhabdomyosarcoma 30.8 ABCB1 EWSR1 FOXO1 MDM2 TP53
9 liposarcoma 30.8 EWSR1 MDM2 TP53
10 malignant mesenchymoma 30.6 EWSR1 MDM2 TP53
11 malignant peripheral nerve sheath tumor 30.0 EGFR MDM2 TP53
12 glioblastoma 28.7 EGFR MDM2 TP53 VEGFA
13 myeloma, multiple 28.4 ABCB1 TNF TP53 VEGFA
14 lymphoma, non-hodgkin, familial 28.4 ABCB1 BCL2 MDM2 TP53
15 lung cancer susceptibility 3 28.4 EGFR TERT TP53 VEGFA
16 small cell cancer of the lung 28.3 ABCB1 EGFR TP53
17 leukemia, acute myeloid 28.2 ABCB1 TERT TNF TP53
18 renal cell carcinoma, nonpapillary 27.8 ABCB1 EGFR IFNG VEGFA
19 ewing sarcoma 26.8 EGFR EWSR1 FOXO1 IFNG MDM2 TNF
20 ovarian cancer 25.5 ABCB1 BCL2 EGFR MDM2 TERT TNF
21 lung cancer 25.2 ABCB1 BCL2 EGFR MDM2 TERT TP53
22 colorectal cancer 24.3 ABCB1 BCL2 EGFR IFNG MDM2 TERT
23 breast cancer 24.2 ABCB1 BCL2 EGFR FOXO1 MDM2 MKI67
24 soft tissue sarcoma childhood 12.2
25 alveolar soft part sarcoma 11.9
26 sarcoma, synovial 11.6
27 dermatofibrosarcoma protuberans 11.5
28 epithelioid sarcoma 11.4
29 malignant fibroxanthoma 11.3
30 sarcoma 11.3
31 hemangiopericytoma, malignant 11.1
32 undifferentiated pleomorphic sarcoma 11.1
33 follicular dendritic cell sarcoma 10.9
34 connective tissue disease 10.9
35 rhabdomyosarcoma, embryonal, 2 10.9
36 synovium cancer 10.9
37 heart malignant hemangiopericytoma 10.9
38 rhabdomyosarcoma, embryonal, 1 10.9
39 ring chromosome 7 10.8 MDM2 TP53
40 zika virus infection 10.8 MDM2 TP53
41 actinic cheilitis 10.8 MDM2 TP53
42 conventional central osteosarcoma 10.8 EWSR1 MDM2
43 tetraploidy 10.7 LATS1 TP53
44 bone osteosarcoma 10.7 EWSR1 MDM2
45 spindle cell lipoma 10.7 FOXO1 MDM2
46 sclerosing liposarcoma 10.7 MDM2 TP53
47 lip cancer 10.7 MDM2 TP53
48 infiltrating angiolipoma 10.6 MDM2 VEGFA
49 staphylococcal toxic shock syndrome 10.6 IFNG TNF
50 spitz nevus 10.6 MKI67 TP53

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.32 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
2 cardiovascular system MP:0005385 10.31 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
3 growth/size/body region MP:0005378 10.31 TP53 VEGFA ABCB1 BCL2 EGFR FOXO1
4 cellular MP:0005384 10.3 TERT TNF TP53 VEGFA BCL2 EGFR
5 digestive/alimentary MP:0005381 10.29 FOXO1 IFNG MDM2 TERT TNF TP53
6 homeostasis/metabolism MP:0005376 10.29 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
7 hematopoietic system MP:0005397 10.26 ABCB1 BCL2 EGFR FOXO1 IFNG MDM2
8 immune system MP:0005387 10.24 VEGFA ABCB1 BCL2 EGFR FOXO1 IFNG
9 mortality/aging MP:0010768 10.22 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
10 craniofacial MP:0005382 10.2 BCL2 EGFR FOXO1 IFNG MDM2 TNF
11 embryo MP:0005380 10.19 EGFR FOXO1 IFNG MDM2 TNF TP53
12 integument MP:0010771 10.18 BCL2 EGFR FOXO1 IFNG LATS1 MDM2
13 liver/biliary system MP:0005370 10.15 LATS1 MDM2 TNF TP53 VEGFA ABCB1
14 neoplasm MP:0002006 10.13 BCL2 EGFR FOXO1 IFNG LATS1 MDM2
15 nervous system MP:0003631 10.1 ABCB1 BCL2 EGFR IFNG LATS1 MDM2
16 no phenotypic analysis MP:0003012 10.07 ABCB1 EGFR FOXO1 IFNG LATS1 MDM2
17 muscle MP:0005369 10.06 BCL2 EGFR FOXO1 IFNG MDM2 TNF
18 limbs/digits/tail MP:0005371 9.99 EGFR FOXO1 MDM2 TNF TP53 VEGFA
19 normal MP:0002873 9.97 EGFR FOXO1 IFNG LATS1 MDM2 MKI67
20 reproductive system MP:0005389 9.9 ABCB1 BCL2 EGFR FOXO1 IFNG LATS1
21 renal/urinary system MP:0005367 9.73 BCL2 EGFR IFNG MDM2 TP53 VEGFA
22 respiratory system MP:0005388 9.43 EGFR IFNG TERT TNF TP53 VEGFA
23 skeleton MP:0005390 9.23 TNF TP53 VEGFA EGFR FOXO1 IFNG

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 609)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
5
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
6
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
7
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
8
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 772 46507594
10
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
11
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
12
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
13
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
14
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
16
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
17
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
18
Enoxaparin Approved Phase 4,Not Applicable 9005-49-6 772
19
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
37 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
38 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50
Tenofovir Phase 4,Phase 3,Not Applicable 147127-20-6 464205

Interventional clinical trials:

(show top 50) (show all 1792)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
4 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
5 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
6 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
7 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
8 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
9 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
10 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
11 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
12 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
13 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
15 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma Unknown status NCT02672527 Phase 3 Trabectedin;Dexamethasone
16 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
17 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
21 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
22 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
23 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
24 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
28 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
29 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
30 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
31 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
32 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
33 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
34 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
35 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
36 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
37 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Completed NCT00870701 Phase 3
38 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
39 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
40 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
41 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
42 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
43 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
44 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
45 A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo
46 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
47 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
48 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
49 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
50 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

# Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 29

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

41
Bone, Lung, T Cells, Uterus, Testes, Brain, Kidney

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 1426)
# Title Authors Year
1
Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma. ( 29437879 )
2018
2
Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. ( 29384032 )
2018
3
CORR InsightsAr: Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443851 )
2018
4
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma. ( 29895706 )
2018
5
Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. ( 29177953 )
2018
6
Radiation-related soft tissue sarcoma in a veterinary technician. ( 29398573 )
2018
7
Allograft Reconstruction of the Extensor Mechanism after Resection of Soft Tissue Sarcoma. ( 29951320 )
2018
8
Advances in the treatment of soft tissue sarcoma: focus on eribulin. ( 29440930 )
2018
9
Long-term results in children with head and neck rhabdomyosarcoma: A report from the Italian Soft Tissue Sarcoma Committee. ( 29115716 )
2018
10
Impact of surgery in patients with metastatic soft tissue sarcoma: A monocentric retrospective analysis. ( 29953623 )
2018
11
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). ( 29383713 )
2018
12
Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas. ( 29297565 )
2018
13
Long-term outcomes of patients with soft tissue sarcoma of the chest wall: Analysis of the prognostic significance of microscopic margins. ( 29434923 )
2018
14
AZGP1 inhibits soft tissue sarcoma cells invasion and migration. ( 29357838 )
2018
15
Body composition predictors of therapy response in patients with primary extremity soft tissue sarcomas. ( 28747130 )
2018
16
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. ( 29902612 )
2018
17
Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma. ( 29411654 )
2018
18
Soft tissue sarcoma affecting the right shoulder of a man with paraplegia from a remote traumatic spinal cord injury: a case report. ( 29951280 )
2018
19
Combined Use of the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as a Prognostic Predictor in Patients with Operable Soft Tissue Sarcoma. ( 29937932 )
2018
20
Near-infrared intraoperative imaging during resection of an anterior mediastinal soft tissue sarcoma. ( 29387401 )
2018
21
Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443850 )
2018
22
The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database. ( 29439175 )
2018
23
Disparities in Perioperative Radiation Therapy Use in Elderly Patients With Soft-Tissue Sarcoma. ( 29958721 )
2018
24
Aggressive Surgical Approach for Treatment of Primary and Recurrent Retroperitoneal Soft Tissue Sarcoma. ( 29915482 )
2018
25
Correction: Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. ( 29339354 )
2018
26
Factors Associated With Acute and Chronic Wound Complications in Patients With Soft Tissue Sarcoma With Long-term Follow-up. ( 29315173 )
2018
27
Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8<sup>+</sup> T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma. ( 29896199 )
2018
28
Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma. ( 29923086 )
2018
29
Magnetic Resonance Imaging-guided Brachytherapy Re-irradiation for Isolated Local Recurrence of Soft Tissue Sarcoma. ( 29888161 )
2018
30
Olaratumab in soft tissue sarcoma - Current status and future perspectives. ( 29413687 )
2018
31
Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. ( 29346043 )
2018
32
Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France. ( 29977133 )
2018
33
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. ( 29900051 )
2018
34
Long-term clinical outcome in patients with high-grade soft tissue sarcoma who were treated with surgical adjuvant therapy using acridine orange after intra-lesional or marginal resection. ( 29885811 )
2018
35
Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population. ( 29900662 )
2018
36
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( 29450452 )
2018
37
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma GroupA study (SSG XX). ( 29929092 )
2018
38
Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. ( 29423096 )
2018
39
Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft Tissue Sarcoma. ( 29491077 )
2018
40
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. ( 28361521 )
2018
41
Adult soft tissue sarcoma and time to treatment initiation: An analysis of the National Cancer Database. ( 29949654 )
2018
42
Surgical Management of Head and Neck Soft Tissue Sarcoma: 11-Year Experience at a Tertiary Care Centre in South India. ( 29887699 )
2018
43
miR-429 inhibits metastasis by targeting KIAA0101 in Soft Tissue Sarcoma. ( 28432002 )
2017
44
The modified Glasgow prognostic score in patients undergoing surgery for bone and soft tissue sarcoma. ( 28342782 )
2017
45
Canine Soft Tissue Sarcomas: Can Being a Dog's Best Friend Help a Child? ( 29218302 )
2017
46
Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. ( 28835514 )
2017
47
Clinicopathological and prognostic value of transforming acidic coiled-coil-containing protein 3 (TACC3) expression in soft tissue sarcomas. ( 29135996 )
2017
48
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal. ( 28914440 )
2017
49
The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series. ( 28202211 )
2017
50
Soft-tissue sarcomas in the head and neck: 25 years of experience. ( 28626490 )
2017

Variations for Soft Tissue Sarcoma

Cosmic variations for Soft Tissue Sarcoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 15

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 BCL2 EGFR IFNG TNF TP53 VEGFA
2
Show member pathways
13.34 BCL2 EGFR FOXO1 MDM2 TNF TP53
3
Show member pathways
13.27 BCL2 EGFR FOXO1 IFNG TNF TP53
4
Show member pathways
12.78 BCL2 EGFR FOXO1 MDM2 TP53 VEGFA
5
Show member pathways
12.71 ABCB1 BCL2 EGFR TERT TP53
6
Show member pathways
12.69 BCL2 EGFR FOXO1 MDM2 TERT TNF
7
Show member pathways
12.67 EGFR FOXO1 MDM2 TP53
8
Show member pathways
12.67 BCL2 EGFR FOXO1 MDM2 TP53 VEGFA
9
Show member pathways
12.61 EGFR IFNG TNF TP53
10
Show member pathways
12.59 BCL2 EGFR IFNG TNF
11
Show member pathways
12.52 BCL2 TNF TP53 VEGFA
12 12.46 LATS1 MDM2 MKI67 TP53
13
Show member pathways
12.44 BCL2 EGFR FOXO1 IFNG TNF TP53
14
Show member pathways
12.42 EGFR FOXO1 MDM2 TP53 VEGFA
15
Show member pathways
12.4 BCL2 EGFR MDM2 TP53
16 12.32 ABCB1 BCL2 EGFR MDM2 TP53 VEGFA
17 12.25 BCL2 IFNG MDM2 TP53
18 12.21 EWSR1 FOXO1 MDM2 TP53
19 12.18 EGFR MDM2 TNF TP53 VEGFA
20 12.07 EGFR IFNG TNF TP53 VEGFA
21 12.06 BCL2 EGFR FOXO1 MDM2 TP53
22
Show member pathways
12.04 EGFR FOXO1 MDM2
23 12.03 BCL2 EGFR MDM2 TP53
24 12.01 EGFR TNF TP53
25 12.01 BCL2 MDM2 TP53 VEGFA
26 11.98 EGFR IFNG TNF TP53
27 11.96 BCL2 TNF TP53
28 11.95 FOXO1 MDM2 TP53
29 11.95 BCL2 EGFR FOXO1 IFNG MDM2 TERT
30 11.94 BCL2 MDM2 TP53
31
Show member pathways
11.94 BCL2 TNF TP53
32 11.94 EGFR FOXO1 MDM2 TP53
33 11.94 BCL2 IFNG TNF TP53 VEGFA
34 11.91 BCL2 IFNG MDM2 TP53
35 11.85 BCL2 EGFR IFNG VEGFA
36 11.83 EGFR FOXO1 MDM2
37 11.83 BCL2 FOXO1 TNF VEGFA
38 11.82 IFNG TNF VEGFA
39 11.82 BCL2 EGFR FOXO1 MDM2 TP53 VEGFA
40 11.78 BCL2 FOXO1 TNF TP53 VEGFA
41 11.77 IFNG MDM2 TP53
42 11.71 BCL2 MDM2 TP53
43 11.66 EGFR IFNG TERT
44 11.66 EGFR MDM2 TP53 VEGFA
45 11.65 ABCB1 TERT VEGFA
46
Show member pathways
11.64 IFNG TNF VEGFA
47 11.57 FOXO1 MDM2 TP53
48 11.56 MDM2 TP53 VEGFA
49 11.49 EGFR TNF VEGFA
50 11.49 EGFR IFNG TNF

GO Terms for Soft Tissue Sarcoma

Cellular components related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.02 EWSR1 MDM2 MKI67 TERT TP53

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.99 FOXO1 IFNG MDM2 TNF TP53
2 positive regulation of cell proliferation GO:0008284 9.98 BCL2 EGFR IFNG MDM2 VEGFA
3 cell proliferation GO:0008283 9.93 BCL2 EGFR MKI67 TP53
4 positive regulation of apoptotic process GO:0043065 9.92 FOXO1 LATS1 TNF TP53
5 positive regulation of gene expression GO:0010628 9.88 IFNG MDM2 TNF TP53 VEGFA
6 positive regulation of protein phosphorylation GO:0001934 9.85 EGFR IFNG TNF VEGFA
7 cytokine-mediated signaling pathway GO:0019221 9.77 BCL2 FOXO1 TNF TP53 VEGFA
8 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR TNF VEGFA
9 humoral immune response GO:0006959 9.74 BCL2 IFNG TNF
10 protein kinase B signaling GO:0043491 9.73 FOXO1 MDM2 TNF
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 MDM2 TERT TNF
12 negative regulation of apoptotic process GO:0043066 9.7 BCL2 EGFR FOXO1 MDM2 TERT TP53
13 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.65 MDM2 TERT
14 positive regulation of osteoclast differentiation GO:0045672 9.65 IFNG TNF
15 negative regulation of gene expression GO:0010629 9.65 IFNG MDM2 TERT TNF VEGFA
16 positive regulation of protein export from nucleus GO:0046827 9.64 MDM2 TP53
17 response to iron ion GO:0010039 9.64 BCL2 MDM2
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IFNG TNF
19 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.63 BCL2 TERT TNF
20 digestive tract morphogenesis GO:0048546 9.62 BCL2 EGFR
21 replicative senescence GO:0090399 9.61 TERT TP53
22 growth GO:0040007 9.61 BCL2 VEGFA
23 negative regulation of mitotic cell cycle GO:0045930 9.61 BCL2 EGFR TNF
24 regulation of mitochondrial membrane permeability GO:0046902 9.6 BCL2 TP53
25 cellular response to actinomycin D GO:0072717 9.51 MDM2 TP53
26 positive regulation of protein complex assembly GO:0031334 9.5 IFNG TNF VEGFA
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
28 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
29 cellular response to hypoxia GO:0071456 9.35 BCL2 MDM2 TERT TP53 VEGFA
30 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.02 BCL2 EGFR LATS1 TNF VEGFA
31 negative regulation of transcription by RNA polymerase II GO:0000122 10.01 FOXO1 IFNG MDM2 TNF TP53 VEGFA

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 9.58 MDM2 TERT TP53
2 ubiquitin protein ligase binding GO:0031625 9.55 BCL2 EGFR FOXO1 MDM2 TP53
3 protease binding GO:0002020 9.54 BCL2 TNF TP53
4 transcription coactivator binding GO:0001223 9.43 FOXO1 TERT
5 protein phosphatase binding GO:0019903 9.43 BCL2 EGFR TP53
6 identical protein binding GO:0042802 9.23 BCL2 EGFR EWSR1 MDM2 TERT TNF
7 protein phosphatase 2A binding GO:0051721 9.13 BCL2 FOXO1 TP53
8 protein binding GO:0005515 10.13 ABCB1 BCL2 EGFR EWSR1 FOXO1 IFNG

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....